CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended				9 Months Ended				77 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013
Revenue	$ 0		$ 0		$ 0		$ 0		$ 0
Operating expense
General & administrative	810,152	[1]	246,086	[1]	1,290,506	[1]	729,569	[1]	8,349,969	[1]
Total operating expense	1,393,728		840,489		2,478,284		2,150,898		14,926,964
Net operating loss	(1,393,728)		(840,489)		(2,478,284)		(2,150,898)		(14,926,964)
Other income (expense)
Interest income	837		26		2,492		768		79,581
Other income	0		0		0		0		244,479
Other expense	(316)		(89)		(661)		(487)		(4,834)
Total Other Income (Expense)	521		(63)		1,831		281		319,226
Net Loss	(1,393,207)		(840,552)		(2,476,453)		(2,150,617)		(14,607,738)
Loss per share
Net loss per share, basic and diluted	$ (0.02)		$ (0.01)		$ (0.04)		$ (0.04)		$ (0.30)
Basic and diluted weighted average number of common shares outstanding	75,380,214		58,902,046		68,068,456		58,717,393		48,619,280
All Other
Operating expense
Research and development	568,576	[2]	546,821	[2]	1,125,711	[2]	994,459	[2]	5,451,308	[2]
MD Anderson for License
Operating expense
Research and development	$ 15,000	[3]	$ 47,582	[3]	$ 62,067	[3]	$ 426,870	[3]	$ 1,125,687	[3]

[1] General & administrative expense includes stock for services, stock option and warrant expenses of $599,424 for the quarter ending 9/30/2013; $609,347 and $3,250 for the nine month periods ending 9/30/2013 and 9/30/2012, respectively; and for the period from inception through 9/30/2013 $3,200,103 for stock option and warrant expense and $318,500 in stock for services.

[2] Research and development expense includes stock option expenses of $6,623 and $11,414 for the quarters ending 9/30/2013 and 9/30/2012, respectively; $26,256 and $42,231 for the nine month periods ending 9/30/2013 and 9/30/2012, respectively; and $449,255 for the period from inception through 9/30/2013. Research and development expense also includes amortization expenses of $40,156 and $48,503 for the quarters ending 9/30/2013 and 9/30/2012, respectively; $120,469 and $145,115 for the nine month periods ending 9/30/2013 and 9/30/2012, respectively; and $1,097,203 for the period from inception through 9/30/2013.

[3] Includes $345,000 technology impairment charge for the nine month period ending 9/30/2012; and $690,000 for the period from inception through 9/30/2013